Simon Walker.

🦋 Today, on #WorldLupusDay, let's highlight the challenges faced by millions worldwide battling #lupus. Together, let's unite to raise awareness! For the latest updates and advancements in lupus research, visit 👉lupushub.com/. 💜 #SLE #WorldLupusDay2024 #LupusAwarenessMonth

Is Lupus Low Disease Activity State (LLDAS) attainment associated with favorable outcomes in patients with newly diagnosed SLE? Find out more and read an expert opinion by Mandana Nikpour here: loom.ly/qqO7JLQ @alberta_hoi @EricFMorand #MedTwitter #RheumTwitter #lupus

CONGRESS #LUPUS2024 | Daphna Paran from Tel Aviv Medical Center, Israel, presents ASSESSLE, a new disease activity score for #SLE. 45 pts were scored. ASSESSLE correlated well with BILAG & SLEDAI & showed similar ability to capture global, mucocutaneous, musculoskeletal & renal disease active domains. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Gergely Bodor, University of Szeged, shares efficacy & safety of CYC vs RTX induction therapy in treating severe #SLE flare. After 12 months, more RTX- vs CYC-treated pts met remission criteria (41.9%% vs 14.8%; p=0.024) and received significantly lower induction & cumulative corticosteroid doses (p<0.001). AEs were numerically higher with CYC. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Diogo Jesus @Hospital_Leiria presents a post-hoc analysis of ph II/III anifrolumab trials assessing ability of SLE-DAS to identify pts with MSDA (N=438). SLE-DAS identified 96.1% & SLEDAI-2K identified 92.9% of these pts. Pts in MSDA by SLE-DAS & SLEDAI-2K showed significantly severe impact all HR-QoL PROs. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Emiliano Marasco @bambinogesu presents a case of refractory childhood-onset #SLE treated with anti-CD19 CAR T-cell therapy. CAR-T cells expanded significantly (peak at D12, 52 cells/uL), achieving complete B-cell depletion by D7. The patient remained in drug-free remission at the last follow-up (Wk10). #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | @daniel_mrak @MedUni_Wien presents real-life drug survival rates in 235 pts with #SLE from Vienna #lupus cohort. The sequence of treatment cycles did now show significant association with overall drug survival, however type of treatment did: CQ/HCQ & MMF showed significantly higher retention rates compared to MTX & AZA (p=0.0016). #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Luxme Nadarajah @NHSBartsHealth presents efficacy of belimumab in pts with #Lupusnephritis refractory to standard therapy (N=12). At 1 yr, 72% pts did not see a fall in eGFR >20%, 40% had uPCR<0.7 g/mol & 58% had SLEDAI≤4. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Mariele Gatto @unito discusses the minimum effective duration of clinical remission capable of protecting against damage accrual /development of impaired kidney function. The increase in SLICC damage index from baseline was significantly higher in pts who never achieved vs. those who achieved remission #Lupus #SLE #Rheumtwitter #medicalcongress

CONGRESS #LUPUS2024 | Ronald van Vollenhoven @ronfvv @UvA_Amsterdam presents post-hoc analysis of phase II PAISLEY trial assessing kinetics of mucocutaneous & musculoskeletal responses to deucravacitinib in pts with #SLE. More deucravacitinib-treated pts achieved SRI(4), CLASI-50, JC-50, & LLDAS responses than placebo-treated pts, with curve separation evident by Wk4. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Takehiro Nakai from St. Luke’s International Hospital, Tokyo, discusses association between clinical remission with active serology/GC dosage on #SLE adverse pregnancy outcomes (N=96). Pregnant pts with clinical remission showed significantly decreased overall, maternal & neonatal APO ratio, while no statistical difference was observed based on serological activity. A prednisolone equivalent GC dose ≥7.5 mg/day at conception was associated with increased APO (p=0.016). #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Tamas Shisha presents interim findings of a phase 1/2 study (NCT05798117) of YTB323 in 6 pts with severe refractory #SLE. Peak expansion of CAR T-cells was observed at D13 & 18 in 2 pts. Safety profile was favourable: no ICANS were reported; CRS events were low-grade & reversible. Considerable reductions in SLEDAI & PhGA along with improvements in disease biomarkers were observed. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Ismail Simsek presents preclinical studies discussing non-redundant roles of dual BAFF/APRIL inhibitor povetacicept vs single BAFF or APRIL inhibitors. Povetacicept had greater distribution to lupus-related tissues in normal mice, downregulated genes associated with B cell activation in cultured PBMC, and suppressed multiple disease parameters & key immune cell subsets in IFNα-accelerated NZB/W lupus model, compared to telitacicept or conventional B cell depletion. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Maria Pappa @uoaofficial presents renal response rates with standard-of-care treatment in 140 real-life pts with #LupusNephritis. With SoC (Initial treatment 51.4% CYC, 32.1% MPA, followed by maintenance therapy) 72.6%, 77.7%, & 69.2% achieved EULAR/ERA-EDTA renal response rates at 3, 6 &12 months, respectively. 20% pts had treatment modification during 12 mo follow-up. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Diogo Jesus presents post-hoc analyses of anifrolumab MUSE, TULIP-1 & -2 trials (N=438). SLE-DAS >9.90 was the best cut-off to identify patients in SDA, with 77.8% sensitivity & 79.6% specificity in the validation cohort. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Pablo Martínez Calabuig @HGUVALENCIA presents real-world effectiveness & safety of belimumab in 15 pts with #SLE. Belimumab exhibited acceptable safety profile, facilitated steroid tapering & improved disease activity markers in all pts. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Laura Salvador Maicas @HGUVALENCIA presents real-world efficacy of anifrolumab in pts with SLE (n=4). All the pts experienced steroid tapering & improvement in ESR levels & SLEDAI/SLE-DAS activity indexes. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Sofia Pitsigavdaki presents a retrospective cohort study assessing attainment of DORIS & LLDAS in pts with moderate-to-severe #SLE (N=348). 38.8% & 77.6% pts achieved sustained DORIS & LLDAS, respectively. DORIS≥50% & LLDAS≥60% of observation time showed best balance between attainability & specificity for damage-free progression. #Lupus #RheumTwitter #MedEd #medicalcongress

CONGRESS #LUPUS2024 | Esra Firat Senturk @iu_cerrahpasa presents effectiveness of rituximab in 47 pts with #LupusNephritis resistant to conventional treatments. 53.1% pts achieved a prednisolone dose of ≤ 5mg & 36.1% achieved 24-h proteinuria ≤ 500 mg. #Lupus #RheumTwitter #MedEd #medicalcongress